Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Marshall S. Stanton sold 26,132 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $28.44, for a total value of $743,194.08. Following the transaction, the senior vice president now directly owns 79,200 shares of the company's stock, valued at approximately $2,252,448. The trade was a 24.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Artivion Trading Down 0.4%
Shares of AORT traded down $0.11 during midday trading on Thursday, reaching $29.66. The company had a trading volume of 286,778 shares, compared to its average volume of 336,984. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $32.33. The company has a quick ratio of 3.95, a current ratio of 5.53 and a debt-to-equity ratio of 1.08. The firm has a 50 day simple moving average of $27.07 and a 200-day simple moving average of $27.48. The stock has a market cap of $1.27 billion, a PE ratio of -59.33 and a beta of 1.62.
Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. The firm had revenue of $98.98 million during the quarter, compared to analysts' expectations of $94.81 million. Research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on AORT. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Stifel Nicolaus reduced their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Canaccord Genuity Group assumed coverage on shares of Artivion in a research note on Tuesday. They issued a "buy" rating and a $35.00 price target on the stock. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $32.00.
Read Our Latest Research Report on AORT
Institutional Trading of Artivion
A number of hedge funds and other institutional investors have recently made changes to their positions in AORT. Wellington Management Group LLP lifted its holdings in Artivion by 4.1% in the first quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company's stock valued at $42,460,000 after acquiring an additional 67,327 shares during the last quarter. Wasatch Advisors LP raised its position in Artivion by 27.7% in the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock valued at $29,791,000 after purchasing an additional 226,160 shares during the period. Next Century Growth Investors LLC lifted its stake in shares of Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company's stock valued at $25,140,000 after purchasing an additional 530,122 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Artivion by 10.0% in the 4th quarter. Northern Trust Corp now owns 463,250 shares of the company's stock valued at $13,244,000 after purchasing an additional 42,170 shares during the last quarter. Finally, Lord Abbett & CO. LLC grew its holdings in shares of Artivion by 31.0% during the 1st quarter. Lord Abbett & CO. LLC now owns 401,904 shares of the company's stock worth $9,879,000 after purchasing an additional 95,202 shares during the period. Institutional investors and hedge funds own 86.37% of the company's stock.
About Artivion
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Stories
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
